A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease

被引:104
作者
Keene, CD [1 ]
Rodrigues, CMP
Eich, T
Linehan-Stieers, C
Abt, A
Kren, BT
Steer, CJ
Low, WC
机构
[1] Univ Minnesota, Sch Med, Grad Program Neurosci, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Sch Med, Dept Neurosurg, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA
[4] Univ Minnesota, Sch Med, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA
[5] Univ Lisbon, Fac Farm, Ctr Patogenese Mol, P-1699 Lisbon, Portugal
关键词
Huntington's disease; 3-nitropropionic acid; bile acid; tauroursodeoxycholic acid; mitochondria; apoptosis; striatum; neuroprotection;
D O I
10.1006/exnr.2001.7755
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
There is currently no effective treatment for Huntington's disease (HD), a progressive, fatal, neurodegenerative disorder characterized by motor and cognitive deterioration. It is well established that HD is associated with perturbation of mitochondrial energy metabolism. Tauroursodeoxycholic acid (TUDCA), a naturally occurring bile acid, can stabilize the mitochondrial membrane, inhibit the mitochondrial permeability transition, decrease free radical formation, and derail apoptotic pathways. Here we report that TUDCA significantly reduced 3-nitropropionic acid (3NP)-mediated striatal neuronal cell death in cell culture. In addition, rats treated with TUDCA exhibited an 80% reduction in apoptosis and in lesion volumes associated with 3-NP administration. Moreover, rats which received a combination of TUDCA + 3-NP exhibited sensorimotor and cognitive task performance that was indistinguishable from that of controls, and this effect persisted at least 6 months. Bile acids have traditionally been used as therapeutic agents for certain liver diseases. This is the first demonstration, however, that a bile acid can be delivered to the brain and function as a neuroprotectant and thus may offer potential therapeutic benefit in the treatment of certain neurodegenerative diseases. (C) 2001 Academic Press.
引用
收藏
页码:351 / 360
页数:10
相关论文
共 63 条
[61]  
Tabrizi SJ, 1999, ANN NEUROL, V45, P25, DOI 10.1002/1531-8249(199901)45:1<25::AID-ART6>3.0.CO
[62]  
2-E
[63]   DNA END LABELING (TUNEL) IN HUNTINGTONS-DISEASE AND OTHER NEUROPATHOLOGICAL CONDITIONS [J].
THOMAS, LB ;
GATES, DJ ;
RICHFIELD, EK ;
OBRIEN, TF ;
SCHWEITZER, JB ;
STEINDLER, DA .
EXPERIMENTAL NEUROLOGY, 1995, 133 (02) :265-272